Home » Topics » BioWorld Science

BioWorld Science
RSS

HIV replication inhibitors detailed in ViiV Healthcare patent

Nov. 4, 2019

Erytech announces new milestones in TRYbeCA1 phase III study of eryaspase

Nov. 4, 2019

Enanta Pharmaceuticals identifies compounds for RSV infections

Nov. 4, 2019

University of Illinois discloses FOXM1 inhibitors

Nov. 4, 2019

Oligomannate approved in China for mild to moderate AD

Nov. 4, 2019

Neuropore Therapies divulges PIK3C3 inhibitors

Nov. 4, 2019

Promentis Pharmaceuticals announces update on phase II development of SXC-2023

Nov. 4, 2019

OB-002 significantly reduces both primary and metastatic breast cancer in vivo

Nov. 4, 2019

BCX-9250 enters phase I development for treatment of fibrodysplasia ossificans progressiva

Nov. 4, 2019

BGS-2019: a new GMPS inhibitor for the treatment of lupus nephritis

Nov. 4, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 12, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026